BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)

Autor: Hugh Mostafid, Lauren Maynard, Richard J. Brough, Jane M Blazeby, Andrew Protheroe, Mark Johnson, Jo Cresswell, Alison Palmer, Robert Huddart, Stephanie Burnett, John D. Kelly, Sanjeev Madaan, Clare Cruickshank, Boxit Investigators, Wei Shen Tan, Emma Hall, Stephen Andrews, Richard Bogle, Nuria Porta

Publikováno v: Kelly, J D, Tan, W S, Porta, N, Mostafid, H, Huddart, R, Protheroe, A, Bogle, R, Blazeby, J, Palmer, A, Cresswell, J, Johnson, M, Brough, R, Madaan, S, Andrews, S, Cruickshank, C, Burnett, S, Maynard, L, Hall, E 2019, ' BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004) ', European Urology, vol. 75, no. 4, pp. 593-601 . https://doi.org/10.1016/j.eururo.2018.09.020

BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy.OBJECTIVE: To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, reduces the risk of recurrence in NMIBC patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a79256327945cbb6d40858348888f007
http://www.scopus.com/inward/record.url?scp=85054078781&partnerID=8YFLogxK